ArticleAmerican journal of translational research2024
Preliminary exploration of the role of CD14 mRNA in coronary artery injury in Kawasaki disease.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveKawasaki disease (KD) is an acute vasculitis that typically occurs in young children and may lead to coronary artery lesions (CALs), but the precise mechanisms that trigger this illness are unclear. We hope to identify some clues to the pathogenesis of KD through clinical sample analysis.
methodsWe included 12 children who had been diagnosed with KD coronary artery lesions (KD-CALs) or KD-no coronary artery lesions (KD-nCALs) and investigated the transcriptome variations of patients with KD in the acute and subacute stages. Further, we enrolled 12 new patients with KD and investigated the expression of CD14 mRNA and the downstream genes A20, A1/BF1_1, and IκBα, via real-time quantitative PCR (qRT-PCR). In addition, we established an animal model of KD-induced coronary inflammation and measured the protein levels of mCD14, IκBα and IL-6 on Day 7 and 14 after completion of modelling. Then, molecular docking was applied to analyse the binding power of the chemical compounds with mCD14.
resultsThe KD-CALs group contained 62 differentially expressed genes (DEGs), which were enriched in the nuclear factor kappa-B (NF-κB) signalling pathway. CD14 mRNA was upregulated in the acute stage, which caused an increase in expression of the downstream genes A20, A1/BF1_1, and IκBα. Molecular docking revealed that the best docking medicine with mCD14 was lupenone. On Day 14 after modelling, there was significant inflammation with infiltration of lymphocytes and macrophages in the coronary endothelium of the mice. Compared with those in the Day 7 group and the control group, the levels of mCD14, IκBα and IL-6 proteins in the coronary endothelium significantly increased in mice in the Day 14 group.
conclusionsCD14 mRNA may regulate IκBα expression and subsequently activate the NF-κB signalling pathway, ultimately causing vasculitis. CD14 mRNA participates in the occurrence of coronary artery injury, and its protein product mCD14 may be a potential therapeutic target for KD-CALs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.